Virios Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in March 2021
February 24 2021 - 07:05AM
Business Wire
Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage
biotechnology company focused on advancing novel antiviral
therapies to treat diseases associated with virally triggered or
maintained immune responses, announced today that Greg Duncan,
Chairman and Chief Executive Officer, will present a company
overview at the H.C. Wainwright Global Life Sciences Conference,
which is taking place March 9 - 10, 2021.
The presentation will focus on the need for new approaches to
treat fibromyalgia (“FM”), the novel antiviral approach being
pursued by Virios, and the potential of IMC-1 as an FM treatment,
based on positive results from a Phase 2 proof of concept clinical
trial. Management will be available to participate in one-on-one
meetings with qualified members of the investor community who are
registered to attend the conference.
A link to the presentation will be available for on-demand
access beginning Tuesday, March 9, 2021, on Virios Therapeutics’
website under the Investors section: Events and Presentations.
About Virios Therapeutics
Virios Therapeutics (Nasdaq: VIRI) is a clinical-stage
biotechnology company focused on advancing novel, dual mechanism
antiviral therapies to treat conditions associated with virally
triggered or maintained immune responses, such as fibromyalgia
(“FM”). Immune responses related to the activation of tissue
resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a
potential root cause triggering and/or sustaining chronic illnesses
such as FM, irritable bowel disease (“IBS”), chronic fatigue
syndrome and other functional somatic syndromes, all of which are
characterized by waxing and waning symptoms with no obvious
etiology. Our lead development candidate (“IMC-1”) is a novel,
proprietary, fixed dose combination of famciclovir and celecoxib
designed to synergistically suppress HSV-1 replication, with the
end goal of reducing virally promoted disease symptoms.
Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome
measures was previously demonstrated in a Phase 2 clinical trial.
These trial results are suggestive that IMC-1 may represent a new
and novel treatment for fibromyalgia. IMC-1 has been granted fast
track designation by the FDA and is currently being tested in a
multi-center, randomized, double-blind, placebo-controlled Phase 2B
trial designed to set the stage for registrational studies. The
company is led by an executive team highly experienced in the
successful development and commercialization of novel therapies.
For more information, please visit www.virios.com/.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on Virios Therapeutics’ current expectations
and are subject to inherent uncertainties, risks and assumptions
that are difficult to predict. Further, certain forward-looking
statements are based on assumptions as to future events that may
not prove to be accurate. These and other risks and uncertainties
are described more fully in the section titled “Risk Factors” in
the final prospectus related to the public offering filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and Virios
Therapeutics, Inc. undertakes no duty to update such information
except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210224005320/en/
Jenny Kobin IR@Virios.com
Virios Therapeutics (NASDAQ:VIRI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Virios Therapeutics (NASDAQ:VIRI)
Historical Stock Chart
From Mar 2023 to Mar 2024